Study of DC-CIK Combined With Chemotherapy for Advanced Solid Tumor

• Status: Recruiting
• Trial end date: 2020-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Combinations of Dendritic cell-activated cytokine-induced killer cell (DC-CIK) With chemotherapy treatment may enhance the immune response and stop cancer cells from growing.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Yantai Yuhuangding Hospital

Criteria

Inclusion Criteria:

1. Patients with treatment-refractory advanced solid cancer can not accept operation;

2. Age 18 to 75 years;

3. Eastern Cooperative Oncology Group (ECOG) score ≤ 2 points;

4. estimate survival > 3 months;

5. Blood White Blood Cell(WBC)≥ 4×109/L, Hb ≥ 100g/L, Platelet Count (PLT)≥ 80×109/L; Alanine amino transferase (ALT) and aspartate amino transferase (AST)≤ 2 times of normal upper value; Serum Cr ≤ 2 normal upper value;

6. Without any other malignant disease;

7. With more than one scalable lesions;

8. Patients Voluntary attempt, and informed consent;

9. Women of child-bearing potential must have a negative pregnancy test because of the potentially dangerous effects of the preparative chemotherapy on the fetus.

Exclusion Criteria:

1. Patients who do not conform to the inclusion criteria;

2. Patients with uncontrolled infection; underlying disease that was severe or life-threatening (such as uncontrolled brain metastasis );

3. Patients who were pregnant or lactating;

4. ECOG perform status ≥ 2;4.

5. Other situations that the researchers considered unsuitable for this study (such as mental illness, drug abuse, etc.)